| scholarly article | Q13442814 |
| P2860 | cites work | Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group | Q72870860 |
| Osteoporosis and fractures following thyrotoxicosis | Q93700834 | ||
| Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study | Q28331612 | ||
| The timed "Up & Go": a test of basic functional mobility for frail elderly persons | Q29615553 | ||
| Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin | Q34048074 | ||
| Sunscreens suppress cutaneous vitamin D3 synthesis | Q34163163 | ||
| Risk factors for falls among elderly persons living in the community | Q34169854 | ||
| Involutional osteoporosis | Q34181888 | ||
| Screening for osteoporosis | Q34204967 | ||
| Vitamin D3 and calcium to prevent hip fractures in elderly women | Q34238774 | ||
| Hormone therapy to prevent disease and prolong life in postmenopausal women | Q34262585 | ||
| Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. | Q34319046 | ||
| Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease | Q34473833 | ||
| Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis | Q34560448 | ||
| Menopausal Estrogen Replacement Therapy and Breast Cancer | Q34745412 | ||
| A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer | Q34747966 | ||
| Bone mineral loss in young women with amenorrhoea | Q35170800 | ||
| Epidemiology of vertebral osteoporosis | Q35345627 | ||
| Perspective. How many women have osteoporosis? | Q35437028 | ||
| Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study | Q35707414 | ||
| Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study | Q35823749 | ||
| Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer | Q35981774 | ||
| Falls Among Older Persons: A Public Health Perspective | Q36183178 | ||
| The prevention and treatment of osteoporosis | Q36367030 | ||
| Predicting vertebral deformity using bone densitometry at various skeletal sites and calcaneus ultrasound | Q36708279 | ||
| Risk prediction in osteoporosis: A theoretic overview | Q36822757 | ||
| The impact of degenerative conditions in the spine on bone mineral density and fracture risk prediction | Q36824243 | ||
| Calcium supplementation and bone loss: a review of controlled clinical trials | Q37763899 | ||
| Interaction of genetic and environmental influences on peak bone density | Q37845149 | ||
| Epidemiology of vertebral fractures in women | Q69737335 | ||
| Continuous estrogen/progestin therapy in menopause | Q69815591 | ||
| Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin | Q69822343 | ||
| Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) | Q69912312 | ||
| Reduced bone mass in daughters of women with osteoporosis | Q69944287 | ||
| Long-term estrogen replacement therapy prevents bone loss and fractures | Q70078558 | ||
| The minimum effective dose of estrogen for prevention of postmenopausal bone loss | Q70357799 | ||
| Effects of various types and dosages of progestogens on the postmenopausal endometrium | Q70486184 | ||
| Thinking straight about calcium | Q70532496 | ||
| Consequences of a hip fracture: a prospective study over 1 year | Q70679051 | ||
| Menopausal estrogen therapy and hip fractures | Q70817200 | ||
| Axial bone mass in older women. Study of Osteoporotic Fractures Research Group | Q70817447 | ||
| The effect of estrogen dose on postmenopausal bone loss | Q71079039 | ||
| Regulation of bone formation by applied dynamic loads | Q71275906 | ||
| Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment | Q71358532 | ||
| Steroid-induced fractures and bone loss in patients with asthma | Q71773998 | ||
| Quantitative ultrasound and vertebral fracture in postmenopausal women. Fracture Intervention Trial Research Group | Q72323745 | ||
| Densitometric and visual observations of spinal radiographs | Q72350411 | ||
| Prevention of spinal osteoporosis in oophorectomised women | Q72436461 | ||
| Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss | Q72471785 | ||
| Reduced creatinine clearance in primary osteoporosis in women | Q72600075 | ||
| Hypothyroidism and enlarging thyroid mass in a young woman | Q72602128 | ||
| Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? | Q72637022 | ||
| Increased bone density in patients on steroids with etidronate | Q72688075 | ||
| Osteoporosis, metabolic aberrations, and increased risk for vertebral fractures after partial gastrectomy | Q72736587 | ||
| Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism | Q72826063 | ||
| Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss | Q72838186 | ||
| Spinal mineral loss in oophorectomized women. Determination by quantitative computed tomography | Q72869365 | ||
| Effect of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism | Q67503405 | ||
| Measurements of broadband ultrasonic attenuation in the calcaneus in premenopausal and postmenopausal women | Q67551073 | ||
| Treatment of postmenopausal osteoporosis with calcitriol or calcium | Q67724718 | ||
| Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women | Q68092542 | ||
| Normal bone mineral density following cure of Cushing's syndrome | Q68095025 | ||
| Falls by elderly people at home: prevalence and associated factors | Q68104109 | ||
| Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy | Q68355279 | ||
| Spinal bone loss and ovulatory disturbances | Q68564219 | ||
| Mortality following hip fracture before and after implementation of the prospective payment system | Q68574975 | ||
| Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women | Q68590210 | ||
| Factors that influence peak bone mass formation: a study of calcium balance and the inheritance of bone mass in adolescent females | Q68602119 | ||
| Osteoporosis in men with idiopathic hypogonadotropic hypogonadism | Q68933066 | ||
| Efficacy of a continuous estrogen-progestin regimen in the menopausal patient | Q69001009 | ||
| Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations? | Q69179291 | ||
| The risk of breast cancer after estrogen and estrogen-progestin replacement | Q69352496 | ||
| Osteoporosis in men with hyperprolactinemic hypogonadism | Q69505200 | ||
| Nasal calcitonin for treatment of established osteoporosis | Q69559909 | ||
| Osteoporosis--an epidemiological perspective: a review | Q69566202 | ||
| The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women | Q69661213 | ||
| A critical review of bone mass and the risk of fractures in osteoporosis | Q37850053 | ||
| Calcaneal ultrasonic measurements discriminate hip fracture independently of bone mass | Q38531913 | ||
| Breast cancer epidemiology | Q39127803 | ||
| Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment | Q39377585 | ||
| Back Pain and Vertebral Crush Fractures: An Unemphasized Mode of Presentation for Primary Hyperparathyroidism | Q39745370 | ||
| Epidemiology of osteoporosis and osteoporotic fractures | Q39832253 | ||
| Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: Review | Q40135871 | ||
| Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis | Q40212779 | ||
| Calcium nutrition and bone health in the elderly | Q40255793 | ||
| Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies | Q40502322 | ||
| Rationale for the use of clodronate in osteoporosis | Q40901500 | ||
| Prevention of involutional bone loss by exercise | Q41042247 | ||
| Baseline measurement of bone mass predicts fracture in white women | Q41223989 | ||
| A prospective study of postmenopausal estrogen therapy and coronary heart disease | Q41504638 | ||
| An epidemiologic study of hip fracture in postmenopausal women | Q41623414 | ||
| Prevention of postmenopausal bone loss by tiludronate | Q41836121 | ||
| Calcitriol treatment is not effective in postmenopausal osteoporosis | Q42202990 | ||
| Pre-existing fractures and bone mass predict vertebral fracture incidence in women | Q43503365 | ||
| Bone gain in young adult women | Q43953423 | ||
| Osteoporotic bone fragility. Detection by ultrasound transmission velocity | Q44292312 | ||
| Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group | Q44331500 | ||
| Estrogen modulates responses of atherosclerotic coronary arteries | Q44614248 | ||
| Is the recommended daily allowance for vitamin D too low for the homebound elderly? | Q44883379 | ||
| A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium | Q44895271 | ||
| Medications and multiple falls in elderly people: the St Louis OASIS study. | Q44900279 | ||
| Age-related decrements in bone mineral density in women over 65. | Q45156737 | ||
| Rate of mortality for elderly patients after fracture of the hip in the 1980's | Q45285200 | ||
| Estrogen replacement therapy and protection from acute myocardial infarction | Q45285547 | ||
| Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. | Q45976835 | ||
| Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group. | Q45999988 | ||
| Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group | Q46315882 | ||
| Results of bone densitometry affect women's decisions about taking measures to prevent fractures | Q46634354 | ||
| Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group | Q46641528 | ||
| Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women | Q47180742 | ||
| Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group | Q48527134 | ||
| Quantitative Computed Tomography of Vertebral Spongiosa: A Sensitive Method for Detecting Early Bone Loss After Oophorectomy | Q50584469 | ||
| Use of the progestogen challenge test to reduce the risk of endometrial cancer. | Q50585426 | ||
| Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. | Q51601017 | ||
| Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. | Q51649000 | ||
| Ethanol reduces bone formation and may cause osteoporosis. | Q51755941 | ||
| The Atlanta FICSIT study: two exercise interventions to reduce frailty in elders. | Q52065090 | ||
| Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. | Q54010104 | ||
| The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT Trials. Frailty and Injuries: Cooperative Studies of Intervention Techniques. | Q54172823 | ||
| Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial | Q55064304 | ||
| Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling | Q57225370 | ||
| A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women | Q57226755 | ||
| Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management | Q60530953 | ||
| Risk of Localized and Widespread Endometrial Cancer in Relation to Recent and Discontinued Use of Conjugated Estrogens | Q60727778 | ||
| Noncontraceptive estrogen use and the risk of breast cancer | Q60727782 | ||
| Prospective trial of oestrogen and calcium in postmenopausal women. | Q64942866 | ||
| Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis | Q67283849 | ||
| Intermittent cyclical etidronate treatment of postmenopausal osteoporosis | Q67300571 | ||
| P433 | issue | 8 | |
| P921 | main subject | Canada | Q16 |
| P304 | page(s) | 1113-1133 | |
| P577 | publication date | 1996-10-01 | |
| P1433 | published in | Canadian Medical Association Journal | Q5030320 |
| P1476 | title | Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada | |
| P478 | volume | 155 |
| Q34300668 | 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. |
| Q73583425 | Awareness and health beliefs of women towards osteoporosis |
| Q39733558 | Bone health in urban midlife Malaysian women: risk factors and prevention |
| Q75215803 | Breaking--bad news: women's experiences of fractures at midlife |
| Q36244609 | Burden of osteoporosis and fractures in developing countries |
| Q36440206 | Canadian Quality Circle pilot project in osteoporosis: rationale, methods, and feasibility. |
| Q37000411 | Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials |
| Q51984056 | Development and validation of the osteoporosis prescreening risk assessment (OPERA) tool to facilitate identification of women likely to have low bone density. |
| Q33788945 | Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. |
| Q33242892 | Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? |
| Q24802074 | Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates |
| Q91588088 | Estimation of Prevalence of Osteoporosis Using OSTA and Its Correlation with Sociodemographic Factors, Disability and Comorbidities |
| Q33955435 | Influence of bone densitometry results on the treatment of osteoporosis. |
| Q52012055 | Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process. |
| Q33954812 | Investigation and treatment of osteoporosis in patients with fragility fractures. |
| Q44540755 | Mortality and morbidity associated with osteoporosis drug treatment following hip fracture |
| Q35084489 | Oral bisphosphonates do not increase the risk of severe upper gastrointestinal complications: a nested case-control study |
| Q35831149 | Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. |
| Q34733243 | Patterns of bone mineral density testing: current guidelines, testing rates, and interventions |
| Q33954236 | Patterns of use of the bone mineral density test in Ontario, 1992-1998. |
| Q92894766 | The effect of alendronate sodium on trabecular bone structure in an osteoporotic rat model |
| Q37407722 | The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study |
| Q34585097 | The underuse of therapy in the secondary prevention of hip fractures |
| Q47615557 | Utilization of bone mineral density testing among breast cancer survivors in British Columbia, Canada |
| Q51805325 | Validation of various osteoporosis risk indices in elderly Chinese females in Singapore. |
| Q34629020 | Women's perceptions of future risk after low-energy fractures at midlife |
Search more.